Annals of Oncology 7:S85-S89, 1996
© 1996 European Society for Medical Oncology
Reviews |
Chemotherapy alone in the treatment of patients with early stage Hodgkin's disease
Biological Response Modifiers Program, Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research and Development Center Frederick MD, U.S.A.
Correspondence to: D. L. Longo, M.D. Biological Response Modifiers Program Division of Cancer Treatment National Cancer Institute-Frederick Cancer Research and Development Center Frederick, MD 21702-1201 U.S.A.
Studies employing chemotherapy in early stage Hodgkin's disease suggest that this approach is at least comparable to radiation therapy in treatment outcome. Since the long-term disease-free survival in early stages approaches 90%, it is unlikely to further improve these results substantially. Thus, the major goal is the reduction of toxicity. The future choice of therapy will be influenced by the long-term toxicity of these approaches which has to be monitored carefully.
chemotherapy, early stages, Hodgkin's disease